초록 ▼

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

대표청구항 ▼

1. A method for treating a metabolic disorder or for increasing satiety in a subject in need thereof, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject. 2. The method of claim 1, wherein said metabolic disorder is obesity. 3. The method of claim 1, where

1. A method for treating a metabolic disorder or for increasing satiety in a subject in need thereof, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject. 2. The method of claim 1, wherein said metabolic disorder is obesity. 3. The method of claim 1, wherein said metabolic disorder is selected from the group comprising metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus (such as, for example, Type 2 Diabetes), glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, cardiac pathology, stroke, non-alcoholic fatty liver disease, hyperglycemia, hepatic steatosis, dyslipidemia, dysfunction of the immune system associated with overweight and obesity, cardiovascular diseases, high cholesterol, elevated triglycerides, asthma, sleep apnoea, osteoarthritis, neuro-degeneration, gallbladder disease, syndrome X, inflammatory and immune disorders, atherogenic dyslipidemia and cancer. 4. A method for increasing energy expenditure of a subject, optionally without impacting the food intake of said subject, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject. 5. (canceled) 6. The method of claim 1, wherein viable cells of Akkermansia muciniphila are administered to the subject in need thereof. 7. The method of claim 1, wherein Akkermansia muciniphila is orally administered. 8. The method of claim 1, wherein an amount of Akkermansia muciniphila ranging from about 1.104 to about 1.1012 cfu, more preferably from about 1.105 to about 1.1011 cfu, or from about 1.106 to about 1.1010 cfu is administered to the subject. 9. The method of claim 1, wherein the Akkermansia muciniphila is administered at least three times a week. 10. The method of claim 1, wherein the Akkermansia muciniphila is co-administered with another probiotic strain and/or with one or more prebiotics. 11. The method of claim 1, wherein the Akkermansia muciniphila is administered as a composition in association with an excipient. 12. The method of claim 11, wherein said composition is a nutritional composition. 13. The method of claim 11, wherein said composition is orally administered. 14. The method of claim 1, wherein the Akkermansia muciniphila is administered as a pharmaceutical composition in association with a pharmaceutically acceptable vehicle. 15. (canceled) 16. A method for promoting weight loss in a subject in need thereof, the method comprising administering Akkermansia muciniphila or fragments thereof to the subject. 17. (canceled)